Hims & Hers Health (HIMS)
Market Price (11/12/2026): $20.29 | Market Cap: $4.8 BilSector: Health Care | Industry: Health Care Services
Hims & Hers Health (HIMS)
Market Price (11/12/2026): $20.29Market Cap: $4.8 BilSector: Health CareIndustry: Health Care Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -46% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, E-commerce & Digital Retail, and Precision Medicine. Themes include Telehealth Platforms, Show more. | Weak multi-year price returns2Y Excs Rtn is -38% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -232 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -8.1% Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 27x Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.2% Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 22% Key risksHIMS key risks include [1] significant regulatory scrutiny and legal challenges over its marketing of compounded GLP-1 weight loss drugs and [2] difficulty achieving consistent profitability due to intense marketing spend and margin pressure from its personalized offerings. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -46% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, E-commerce & Digital Retail, and Precision Medicine. Themes include Telehealth Platforms, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -38% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -232 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -8.1% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 27x |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.2% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 22% |
| Key risksHIMS key risks include [1] significant regulatory scrutiny and legal challenges over its marketing of compounded GLP-1 weight loss drugs and [2] difficulty achieving consistent profitability due to intense marketing spend and margin pressure from its personalized offerings. |
Qualitative Assessment
AI Analysis | Feedback
Prices as of 11/11/2026
Nov 11: up 8.8% in one day (S&P 500 up 1.3%)
No company news reports explained the stock's significant rise. While the market was also up, headlines on the day reported shares dipping after third-quarter earnings, revenue miss, margin contraction, and reduced guidance.
Down 43.4% from its Aug 21 high to Nov 10, up 8.8% since (S&P 500 down 2.1%)
The stock's decline was primarily driven by company-specific negative news regarding third-quarter financial results, alongside general market downturns. The largest drops occurred on November 5th, influenced by a broad market decline, and on November 9th and 10th following disappointing earnings.
Nov 10: down 16.6% the day after its Nov 9 earnings report (S&P 500 down 0.4%)
The stock plunged in reaction to its third-quarter financial results, which reported missed earnings and revenue estimates, alongside a narrowed full-year sales outlook. Net income and diluted EPS were significantly down year-over-year, with the earnings call also highlighting marketing reset, margin pressure, and subscriber losses.
Nov 11: up 8.8% in one day (S&P 500 up 1.3%)
No company news reports explained the stock's significant rise. While the market was also up, headlines on the day reported shares dipping after third-quarter earnings, revenue miss, margin contraction, and reduced guidance.
Down 43.4% from its Aug 21 high to Nov 10, up 8.8% since (S&P 500 down 2.1%)
The stock's decline was primarily driven by company-specific negative news regarding third-quarter financial results, alongside general market downturns. The largest drops occurred on November 5th, influenced by a broad market decline, and on November 9th and 10th following disappointing earnings.
Nov 10: down 16.6% the day after its Nov 9 earnings report (S&P 500 down 0.4%)
The stock plunged in reaction to its third-quarter financial results, which reported missed earnings and revenue estimates, alongside a narrowed full-year sales outlook. Net income and diluted EPS were significantly down year-over-year, with the earnings call also highlighting marketing reset, margin pressure, and subscriber losses.
Prices as of 11/11/2026
Nov 11: up 8.8% in one day (S&P 500 up 1.3%)
No company news reports explained the stock's significant rise. While the market was also up, headlines on the day reported shares dipping after third-quarter earnings, revenue miss, margin contraction, and reduced guidance.
Down 43.4% from its Aug 21 high to Nov 10, up 8.8% since (S&P 500 down 2.1%)
The stock's decline was primarily driven by company-specific negative news regarding third-quarter financial results, alongside general market downturns. The largest drops occurred on November 5th, influenced by a broad market decline, and on November 9th and 10th following disappointing earnings.
Nov 10: down 16.6% the day after its Nov 9 earnings report (S&P 500 down 0.4%)
The stock plunged in reaction to its third-quarter financial results, which reported missed earnings and revenue estimates, alongside a narrowed full-year sales outlook. Net income and diluted EPS were significantly down year-over-year, with the earnings call also highlighting marketing reset, margin pressure, and subscriber losses.
Show less
Nov 11: up 8.8% in one day (S&P 500 up 1.3%)
No company news reports explained the stock's significant rise. While the market was also up, headlines on the day reported shares dipping after third-quarter earnings, revenue miss, margin contraction, and reduced guidance.
Down 43.4% from its Aug 21 high to Nov 10, up 8.8% since (S&P 500 down 2.1%)
The stock's decline was primarily driven by company-specific negative news regarding third-quarter financial results, alongside general market downturns. The largest drops occurred on November 5th, influenced by a broad market decline, and on November 9th and 10th following disappointing earnings.
Nov 10: down 16.6% the day after its Nov 9 earnings report (S&P 500 down 0.4%)
The stock plunged in reaction to its third-quarter financial results, which reported missed earnings and revenue estimates, alongside a narrowed full-year sales outlook. Net income and diluted EPS were significantly down year-over-year, with the earnings call also highlighting marketing reset, margin pressure, and subscriber losses.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -25.1% change in HIMS stock from 7/31/2026 to 11/11/2026 was primarily driven by a -36.6% change in the company's P/S Multiple.| (LTM values as of) | 7312026 | 11112026 | Change |
|---|---|---|---|
| Stock Price ($) | 27.77 | 20.81 | -25.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,370 | 2,870 | 21.1% |
| P/S Multiple | 2.7 | 1.7 | -36.6% |
| Shares Outstanding (Mil) | 228 | 234 | -2.3% |
| Cumulative Contribution | -25.1% |
Market Drivers
7/31/2026 to 11/11/2026| Return | Correlation | |
|---|---|---|
| HIMS | -25.1% | |
| Market (SPY) | 1.7% | 40.7% |
| Sector (XLV) | 16.2% | 23.5% |
Fundamental Drivers
The -23.4% change in HIMS stock from 4/30/2026 to 11/11/2026 was primarily driven by a -35.5% change in the company's P/S Multiple.| (LTM values as of) | 4302026 | 11112026 | Change |
|---|---|---|---|
| Stock Price ($) | 27.17 | 20.81 | -23.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,348 | 2,870 | 22.2% |
| P/S Multiple | 2.6 | 1.7 | -35.5% |
| Shares Outstanding (Mil) | 227 | 234 | -2.9% |
| Cumulative Contribution | -23.4% |
Market Drivers
4/30/2026 to 11/11/2026| Return | Correlation | |
|---|---|---|
| HIMS | -23.4% | |
| Market (SPY) | 6.0% | 39.6% |
| Sector (XLV) | 30.0% | -0.4% |
Fundamental Drivers
The -54.2% change in HIMS stock from 10/31/2025 to 11/11/2026 was primarily driven by a -66.5% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 11112026 | Change |
|---|---|---|---|
| Stock Price ($) | 45.46 | 20.81 | -54.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,014 | 2,870 | 42.5% |
| P/S Multiple | 5.1 | 1.7 | -66.5% |
| Shares Outstanding (Mil) | 224 | 234 | -4.0% |
| Cumulative Contribution | -54.2% |
Market Drivers
10/31/2025 to 11/11/2026| Return | Correlation | |
|---|---|---|
| HIMS | -54.2% | |
| Market (SPY) | 12.3% | 39.0% |
| Sector (XLV) | 32.7% | 5.2% |
Fundamental Drivers
The 248.0% change in HIMS stock from 10/31/2023 to 11/11/2026 was primarily driven by a 303.7% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312023 | 11112026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.98 | 20.81 | 248.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 711 | 2,870 | 303.7% |
| P/S Multiple | 1.8 | 1.7 | -3.3% |
| Shares Outstanding (Mil) | 208 | 234 | -10.9% |
| Cumulative Contribution | 248.0% |
Market Drivers
10/31/2023 to 11/11/2026| Return | Correlation | |
|---|---|---|
| HIMS | 248.0% | |
| Market (SPY) | 87.9% | 36.4% |
| Sector (XLV) | 58.9% | 12.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| HIMS Return | -55% | -2% | 39% | 172% | 34% | -36% | 43% |
| Peers Return | 30% | 3% | -8% | 0% | 20% | 29% | 90% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 100% |
Monthly Win Rates [3] | |||||||
| HIMS Win Rate | 25% | 58% | 50% | 67% | 50% | 45% | |
| Peers Win Rate | 60% | 52% | 40% | 52% | 62% | 58% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 36% | |
Max Drawdowns [4] | |||||||
| HIMS Max Drawdown | -78% | -54% | -52% | -45% | -63% | -59% | |
| Peers Max Drawdown | -21% | -24% | -26% | -22% | -21% | -18% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ADUS, CVS, CI, LH, DGX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/11/2026 (YTD)
How Low Can It Go
| Event | HIMS | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -23.7% | -7.8% |
| % Gain to Breakeven | 31.0% | 8.5% |
| Time to Breakeven | 61 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -30.4% | -9.5% |
| % Gain to Breakeven | 43.6% | 10.5% |
| Time to Breakeven | 32 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -14.0% | -6.7% |
| % Gain to Breakeven | 16.3% | 7.1% |
| Time to Breakeven | 190 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -53.9% | -24.5% |
| % Gain to Breakeven | 117.0% | 32.4% |
| Time to Breakeven | 91 days | 427 days |
In The Past
Hims & Hers Health's stock fell -23.7% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 31.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | HIMS | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -23.7% | -7.8% |
| % Gain to Breakeven | 31.0% | 8.5% |
| Time to Breakeven | 61 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -30.4% | -9.5% |
| % Gain to Breakeven | 43.6% | 10.5% |
| Time to Breakeven | 32 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -53.9% | -24.5% |
| % Gain to Breakeven | 117.0% | 32.4% |
| Time to Breakeven | 91 days | 427 days |
In The Past
Hims & Hers Health's stock fell -23.7% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 31.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Hims & Hers Health (HIMS)
Hims & Hers Health, Inc. (HIMS) operates as a multi-specialty telehealth platform, connecting consumers directly with licensed healthcare professionals for virtual consultations. Beyond its core telehealth services, the company functions as a direct-to-consumer brand, selling a comprehensive range of health and wellness products and services through its websites and mobile application. Its business model caters primarily to individuals seeking solutions in key areas such as general wellness, sexual health and wellness, skincare, and hair care.
The company's offerings are diverse, including prescription medications provided on a recurring basis, often coupled with ongoing care from healthcare providers. Additionally, Hims & Hers provides a curated selection of non-prescription products such as over-the-counter drugs, cosmetic items, and dietary supplements. Specific examples include vitamin C and collagen for wellness, moisturizers and serums for skincare, condoms and vibrators for sexual health, and shampoos and topical treatments like minoxidil for hair care. Hims & Hers also extends its reach by offering health and wellness products through wholesale partners, serving a broad market of consumers looking for accessible health solutions.
AI Analysis | Feedback
Here are 2 brief analogies for Hims & Hers Health:
- It's like Teladoc Health combined with a modern online pharmacy and wellness store for personal care needs.
- It's the Dollar Shave Club for online prescriptions and wellness products related to hair loss, skincare, and sexual health.
AI Analysis | Feedback
- Telehealth Platform & Medical Consultations: A multi-specialty digital platform connecting consumers with licensed healthcare professionals for virtual consultations and ongoing care.
- Prescription Medications: Offers various prescription drugs on a recurring basis, often facilitated by provider consultations and ongoing support.
- Over-the-Counter (OTC) Products: Provides a curated selection of non-prescription drugs, devices, cosmetics, and supplements for wellness, sexual health, skincare, and hair care.
AI Analysis | Feedback
Hims & Hers Health (HIMS) primarily sells its products and services directly to individual consumers.
The company serves the following categories of customers:
- Wellness and General Health Customers: Individuals seeking general health and wellness products, including supplements like vitamin C, melatonin, biotin, and collagen protein, as well as medical consultation services for various health needs.
- Sexual Health and Wellness Customers: Individuals looking for products and services related to sexual health, such as condoms, climax delay spray and wipes, vibrators, lubricants, and prescription medication for sexual health concerns.
- Skincare and Hair Care Customers: Individuals seeking solutions for skincare issues, including moisturizers, serums, and face washes, and those looking for hair care products like shampoos, conditioners, scalp scrubs, and topical treatments such as minoxidil.
AI Analysis | Feedback
- Truepill (Private Company)
AI Analysis | Feedback
Andrew Dudum
Chief Executive Officer
Andrew Dudum co-founded Hims & Hers in 2016 and has served as its CEO since inception. He is also a co-founder of Atomic Labs, a startup studio and investment fund backed by prominent investors such as Peter Thiel and Marc Andreessen, where he played an integral role in developing over a dozen companies including Bungalow, Homebound, TalkIQ, and Terminal. Dudum is an active angel investor and advisor to various startup companies, including Cherubic Ventures. Prior to Atomic, he co-founded LendforPeace, a nonprofit microlending site. He also worked at TokBox, a video-chat startup that was subsequently acquired. Hims & Hers went public via a SPAC in 2020, debuting on the New York Stock Exchange in January 2021 at a $1.6 billion valuation.
Yemi Okupe
Chief Financial Officer
Yemi Okupe joined Hims & Hers as Chief Financial Officer in January 2022. He brings extensive experience from financial leadership positions at high-growth, B2C companies. From 2019 to 2021, Okupe served as Divisional CFO at Uber, where he was responsible for UberEats and Uber's global mobility unit. His career also includes various financial leadership roles at eBay and PayPal, including Divisional CFO of Braintree, and he was the finance lead for Google Payments and Google Express at Google. Prior to joining Hims & Hers, he served as CFO of Hipcamp.
Mike Chi
Chief Operating Officer
Mike Chi joined Hims & Hers in April 2021 as Chief Operating Officer. He possesses over 20 years of experience in consumer-focused businesses, specializing in brand positioning, growth marketing, product management, and merchandising strategy. Before his role at Hims & Hers, Chi was the Chief Marketing Officer at Zola, an online wedding planning platform. He also held positions as Vice President of Marketing and digital experience at INTERMIX and various senior roles in marketing and general management at Gilt Groupe.
Dr. Patrick Carroll
Chief Medical Officer
Dr. Patrick Carroll re-joined Hims & Hers as Chief Medical Officer in December 2022 and also serves as a board member. He previously held the CMO position at Hims & Hers from June 2019 through January 2022. Between his two tenures with Hims & Hers, Dr. Carroll was the Chief Medical Officer of Vida Health, a virtual care company. Prior to his initial role at Hims & Hers, he served for five years as Group Vice President and Chief Medical Officer of Walgreens, where he oversaw retail clinics, healthcare strategy, and quality programs. His experience also includes CMO roles at Integrated Care Partners (Hartford HealthCare's clinical integration organization) and Granite Medical Group.
Dheerja Kaur
Chief Product Officer
Dheerja Kaur joined Hims & Hers in July 2025 as Chief Product Officer. She brings nearly two decades of experience in building category-defining products and services. Most recently, she served as VP of Product at Robinhood, where she was instrumental in scaling their business and led Robinhood Gold, a premium membership offering that reached over 3 million subscribers. She also previously held the position of Chief Product Officer at The Skimm.
AI Analysis | Feedback
The key risks to Hims & Hers Health (HIMS) include regulatory and legal scrutiny, intense competition, and challenges related to its reliance on compounded medications.
*
Regulatory and Legal Scrutiny
Hims & Hers Health faces significant regulatory scrutiny from the U.S. Food and Drug Administration (FDA) and other bodies, particularly concerning its compounded medication offerings and marketing practices. The FDA has issued warning letters to telehealth companies, including Hims & Hers, for promoting compounded versions of GLP-1 weight-loss drugs with misleading claims. This regulatory action forced Hims & Hers to withdraw its discounted version of Novo Nordisk's GLP-1 therapy, Wegovy, in the past. While a recent partnership with Novo Nordisk to offer branded GLP-1 medications has eased some legal and regulatory overhangs, the ongoing FDA scrutiny of compounded weight-loss drugs remains a structural risk to the company's business model. The company has also faced a U.S. Securities and Exchange Commission (SEC) investigation. *Intense Competition
The telehealth and direct-to-consumer healthcare sectors are highly competitive, with Hims & Hers facing numerous rivals. Direct competitors like Ro (Roman) and Keeps offer similar direct-to-consumer models, competing on factors such as pricing, brand recognition, and the range of health offerings. Broader telehealth platforms such as Teladoc Health also present a significant competitive challenge. This intense market environment necessitates continuous innovation and efficient operations, potentially pressuring pricing and profitability. *Reliance on Compounded Medications and Market Shifts
Hims & Hers' growth has been significantly accelerated by its expansion into offerings such as GLP-1 weight loss treatments, which historically included compounded versions of these drugs. However, regulatory changes and increased enforcement, particularly regarding compounded GLP-1 medications, have compromised this strategy. The expiration of COVID-19-era telehealth waivers and evolving regulations concerning compounded drugs create a complex compliance landscape. While the company is adapting by partnering with pharmaceutical manufacturers for branded products, the capital and effort invested in compounding infrastructure may generate poor returns as the company navigates this transition. This shift could also impact their growth trajectory and margins if branded GLP-1s consolidate power back to pharmaceutical-controlled channels.AI Analysis | Feedback
The aggressive expansion of Amazon (through Amazon Clinic and Amazon Pharmacy) into direct-to-consumer telehealth consultations and online prescription medication fulfillment represents a clear emerging threat. Amazon's vast logistics network, established customer base, and ability to offer competitive pricing could significantly disrupt Hims & Hers Health's core business model of connecting consumers to healthcare professionals and delivering prescription and over-the-counter products directly to them.
AI Analysis | Feedback
Addressable Markets for Hims & Hers Health (HIMS)
Hims & Hers Health, Inc. operates in several significant addressable markets related to telehealth, prescription medication, over-the-counter products, and health and wellness supplements. The market sizes for their main products and services are as follows:
- Telehealth Platform: The U.S. telehealth market size is estimated at approximately USD 52.77 billion in 2025 and is projected to reach around USD 447.69 billion by 2035.
- Sexual Health and Wellness: The U.S. sexual wellness market is estimated at USD 23.25 billion in 2025 and is projected to reach approximately USD 49.92 billion by 2035.
- Skincare: The U.S. skincare market is estimated to be around USD 24 billion in annual revenue in 2025 and is expected to grow to USD 30.60 billion by 2030.
- Hair Care: The U.S. hair care market size is valued at USD 20.12 billion in 2025, estimated at USD 20.98 billion in 2026, and projected to reach USD 25.9 billion by 2031.
- Wellness Supplements: The North America dietary supplements market, which includes wellness supplements, is estimated at USD 64.06 billion in 2025 and is projected to reach USD 91.30 billion by 2030.
- Over-the-Counter (OTC) Drugs: The U.S. over-the-counter (OTC) drugs market size is estimated at USD 54.6 billion in 2025 and is expected to grow to USD 86.3 billion by 2034.
- Direct-to-Consumer (DTC) Weight-Loss Medication: The global direct-to-consumer (DTC) weight-loss medication market size is valued at USD 8.64 billion in 2025 and is estimated to reach USD 35.61 billion by 2034. North America holds the largest share of this market.
AI Analysis | Feedback
Hims & Hers Health (HIMS) is expected to drive future revenue growth over the next 2-3 years through several key strategies:
* Expansion into New Therapeutic Categories and Personalized Treatments: The company anticipates significant revenue growth from expanding its offerings into new health specialties. This includes the substantial growth propelled by its weight management category, with projections for it to be a primary driver of revenue. Further expansion into hormonal health, specifically menopause and low testosterone treatments, is also a key focus, targeting large market opportunities in the United States. Additionally, the integration of lab testing is expected to broaden personalized treatment options, and the overall strategy involves evolving personalized solutions to encompass multi-condition treatments and new form factors, aiming for continued market share gains and enhanced patient lifetime value.
* International Market Expansion: Hims & Hers is actively pursuing a global expansion strategy to enhance its market position. This involves strategic acquisitions, such as ZAVA in Europe (extending its footprint across the U.K., Germany, France, and Ireland) and Eucalyptus (expanding presence into regions like Australia and Japan). The company also plans entry into new geographies, including Canada in 2026, which is expected to make weight loss treatments more accessible. Management has set an ambitious goal to scale its international business to over $1 billion in annual revenue within three years, with at least $200 million in revenue contributions projected from international markets in 2026.
* Subscriber Growth and Enhanced Customer Engagement: A core driver of revenue growth is the continuous expansion of the company's subscriber base and increasing the monthly revenue generated per average subscriber. This is achieved through effective user acquisition strategies, robust retention initiatives, and broadening the array of product and service offerings available on its direct-to-consumer platform. The company's business model is largely subscription-based, indicating a high degree of recurring revenue and customer loyalty.
* Strategic Partnerships for Branded Medications: Hims & Hers is strengthening its market position through strategic collaborations with pharmaceutical companies. A notable example is its partnership with Novo Nordisk to distribute branded weight-loss medicines, such as Ozempic and Wegovy. This move signifies a shift from reliance on compounded drugs to officially offering brand-name medications, which is anticipated to bolster credibility, expand treatment options, attract more customers, and drive significant revenue growth by enhancing user trust and platform stickiness.
AI Analysis | Feedback
Share Repurchases
- Hims & Hers Health authorized a new share repurchase program of up to $250 million of its Class A common stock in November 2025, effective through November 11, 2028.
- This new program followed the completion of a prior $100 million share repurchase program, which commenced in July 2024.
- The company repurchased $89.96 million in shares in 2025 and $83.039 million in 2024.
Share Issuance
- Hims & Hers Health became a public company in January 2021 through a merger with Oaktree Acquisition Corp. II, a Special Purpose Acquisition Company (SPAC), which brought in nearly $280 million for expansion initiatives.
- In 2025, the company recorded $970 million in proceeds from the issuance of convertible senior notes, net of debt discount.
Inbound Investments
- In January 2019, Hims raised $100 million in a Series C funding round, which valued the company at $1 billion pre-money.
- The SPAC merger in January 2021 injected approximately $280 million into the company for growth and expansion efforts.
Outbound Investments
- In February 2026, Hims & Hers acquired Eucalyptus, an Australian digital health platform operating Juniper, Pilot, and Kin, in a deal valued at $1.6 billion. The acquisition involved an initial cash payment of approximately $240 million, with the remainder paid over 18 months.
- In June 2025, the company acquired ZAVA, a European digital health platform, which expanded its presence in the U.K., Germany, France, and Ireland through an all-cash transaction.
- Hims & Hers also acquired London-based Honest Health in 2021.
Capital Expenditures
- Capital expenditures for Hims & Hers Health peaked at $226 million in fiscal year 2025, increasing significantly from $41.655 million in 2024, $17.22 million in 2023, and $2.714 million in 2022.
- The company anticipates continued investment in existing and new offerings, AI-driven tools, and international expansion in 2026.
- Hims & Hers entered a long-term lease for a large facility in New Albany, Ohio, designated for office, research and development, laboratory, manufacturing, and pharmaceutical dispensing activities.
Peer Outperformance in Health Care Services
HIMS has outperformed 100% of its 19 Health Care Services peers over 5Y. Health Care Services ranks 2nd of 10 industries in Health Care by median 5Y return. That makes it one of the strongest corners of the sector.
Share of Health Care Services constituents that HIMS has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
5%
of 21 industry peers · -47.6% return
3Y
95%
of 19 industry peers · 205.6% return
5Y
100%
of 19 industry peers · 170.3% return
No Health Care Services peer with a comparable growth profile has beaten HIMS by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Health Care Services is HIMS's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 23.7% | 107.0% | 103.1% | CAH 516% · MCK 396% · COR 193% |
| Health Care Services ← | 20 | 31.7% | 27.6% | 12.4% | HIMS 170% · RDNT 147% · DGX 92% |
| Managed Health Care | 8 | 65.8% | -1.7% | 0.8% | OSCR 157% · HQY 49% · ELV 7% |
| Health Care Facilities | 26 | 24.0% | 20.4% | -5.7% | THC 269% · NHC 227% · EHC 193% |
| Health Care Equipment | 50 | 4.3% | 19.7% | -11.9% | GKOS 382% · UFPT 363% · TMDX 241% |
| Pharmaceuticals | 60 | -13.9% | 19.0% | -38.7% | LQDA 968% · XERS 694% · KNSA 623% |
| Health Care Supplies | 11 | 24.5% | 17.4% | -38.7% | LNTH 239% · HAE 104% · MMSI 30% |
| Life Sciences Tools & Services | 109 | -9.4% | -4.9% | -75.0% | AXGN 361% · MEDP 201% · NTRA 183% |
| Biotechnology | 364 | -25.0% | -29.2% | -80.8% | ELVN 1284% · TRVI 1156% · DNTH 1102% |
| Health Care Technology | 22 | -19.9% | -45.0% | -82.6% | VEEV -3% · DOCS -57% |
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 193.77 |
| Mkt Cap | 29.5 |
| Rev LTM | 13,218 |
| Op Inc LTM | 1,686 |
| FCF LTM | 1,331 |
| FCF 3Y Avg | 1,217 |
| CFO LTM | 1,883 |
| CFO 3Y Avg | 1,707 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.0% |
| Rev Chg 3Y Avg | 11.0% |
| Rev Chg Q | 7.0% |
| QoQ Delta Rev Chg LTM | 1.7% |
| Op Inc Chg LTM | 16.5% |
| Op Inc Chg 3Y Avg | 13.6% |
| Op Mgn LTM | 7.0% |
| Op Mgn 3Y Avg | 6.4% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 8.2% |
| CFO/Rev 3Y Avg | 11.0% |
| FCF/Rev LTM | 6.3% |
| FCF/Rev 3Y Avg | 7.2% |
Price Behavior
Price Behavior
| Market Price | $20.81 | |
| Market Cap ($ Bil) | 4.9 | |
| First Trading Date | 09/13/2019 | |
| Distance from 52W High | -48.0% | |
| 50 Days | 200 Days | |
| DMA Price | $27.95 | $26.77 |
| DMA Trend | down | down |
| Distance from DMA | -25.5% | -22.3% |
| 3M | 1YR | |
| Volatility | 84.4% | 92.7% |
| Downside Capture | 440.24 | 382.10 |
| Upside Capture | 308.64 | 253.78 |
| Correlation (S&P 500) | 34.0% | 38.8% |
HIMS Betas & Captures as of 10/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.68 | 2.62 | 3.23 | 2.80 | 2.81 | 2.29 |
| Up Beta | -2.56 | -0.86 | 1.72 | 2.85 | 2.40 | 1.24 |
| Down Beta | 2.65 | 4.74 | 3.08 | 1.88 | 2.45 | 2.25 |
| Up Capture | 447% | 255% | 444% | 454% | 554% | 21810% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 9 | 20 | 31 | 64 | 111 | 376 |
| Down Capture | 409% | 235% | 304% | 231% | 180% | 113% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 12 | 22 | 32 | 59 | 136 | 367 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HIMS | |
|---|---|---|---|---|
| HIMS | -49.4% | 92.7% | -0.33 | - |
| Sector ETF (XLV) | 30.1% | 17.0% | 1.37 | 5.3% |
| Equity (SPY) | 12.5% | 13.7% | 0.60 | 38.9% |
| Gold (GLD) | -3.5% | 28.8% | -0.13 | 17.5% |
| Commodities (DBC) | 33.0% | 21.3% | 1.24 | -8.2% |
| Real Estate (VNQ) | 11.7% | 14.2% | 0.53 | 4.0% |
| Bitcoin (BTCUSD) | -30.9% | 43.5% | -0.73 | 28.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HIMS | |
|---|---|---|---|---|
| HIMS | 20.3% | 85.0% | 0.59 | - |
| Sector ETF (XLV) | 8.6% | 15.4% | 0.36 | 19.1% |
| Equity (SPY) | 11.8% | 17.3% | 0.51 | 39.1% |
| Gold (GLD) | 17.1% | 19.2% | 0.72 | 8.6% |
| Commodities (DBC) | 7.9% | 19.6% | 0.29 | 4.4% |
| Real Estate (VNQ) | 1.3% | 18.9% | -0.04 | 23.1% |
| Bitcoin (BTCUSD) | 3.1% | 51.5% | 0.24 | 24.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HIMS | |
|---|---|---|---|---|
| HIMS | 7.8% | 78.0% | 0.48 | - |
| Sector ETF (XLV) | 12.8% | 16.8% | 0.63 | 14.5% |
| Equity (SPY) | 15.5% | 18.0% | 0.73 | 28.8% |
| Gold (GLD) | 11.5% | 16.6% | 0.57 | 8.3% |
| Commodities (DBC) | 7.4% | 18.2% | 0.33 | 3.7% |
| Real Estate (VNQ) | 6.1% | 20.7% | 0.25 | 16.4% |
| Bitcoin (BTCUSD) | 58.6% | 66.3% | 0.99 | 18.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 11/12/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/9/2026 | -16.6% | ||
| 8/10/2026 | -4.0% | -9.9% | -12.2% |
| 5/11/2026 | -14.1% | -23.5% | -4.7% |
| 2/23/2026 | -0.3% | 6.3% | 37.6% |
| 11/3/2025 | -3.6% | -7.5% | -9.8% |
| 8/4/2025 | -12.4% | -21.1% | -29.8% |
| 5/5/2025 | 18.1% | 31.8% | 28.0% |
| 2/24/2025 | -22.3% | -20.7% | -27.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 12 | 12 |
| # Negative | 15 | 11 | 11 |
| Median Positive | 13.1% | 15.9% | 37.1% |
| Median Negative | -5.8% | -9.9% | -18.1% |
| Max Positive | 31.0% | 44.9% | 86.7% |
| Max Negative | -22.3% | -23.5% | -30.0% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/9/2026 | -16.6% | ||
| 8/10/2026 | -4.0% | -9.9% | -12.2% |
| 5/11/2026 | -14.1% | -23.5% | -4.7% |
| 2/23/2026 | -0.3% | 6.3% | 37.6% |
| 11/3/2025 | -3.6% | -7.5% | -9.8% |
| 8/4/2025 | -12.4% | -21.1% | -29.8% |
| 5/5/2025 | 18.1% | 31.8% | 28.0% |
| 2/24/2025 | -22.3% | -20.7% | -27.8% |
| 11/4/2024 | -0.6% | 34.3% | 63.4% |
| 8/5/2024 | -5.4% | -10.5% | -18.1% |
| 5/6/2024 | 6.0% | 10.6% | 86.7% |
| 2/26/2024 | 31.0% | 43.4% | 54.3% |
| 11/6/2023 | 11.0% | 11.5% | 41.7% |
| 8/7/2023 | -5.8% | -9.9% | -12.5% |
| 5/8/2023 | -10.1% | -9.1% | -22.7% |
| 2/27/2023 | 16.8% | 4.4% | 2.7% |
| 11/7/2022 | 19.7% | 30.5% | 51.5% |
| 8/8/2022 | -5.1% | 8.2% | -2.4% |
| 5/9/2022 | -6.5% | -6.5% | 13.2% |
| 2/22/2022 | 13.1% | 20.2% | 25.7% |
| 11/10/2021 | -4.0% | 1.2% | -23.9% |
| 8/11/2021 | 10.8% | -2.6% | 15.1% |
| 5/17/2021 | 4.2% | 44.9% | 36.5% |
| 3/18/2021 | -9.7% | -18.6% | -30.0% |
| SUMMARY STATS | |||
| # Positive | 9 | 12 | 12 |
| # Negative | 15 | 11 | 11 |
| Median Positive | 13.1% | 15.9% | 37.1% |
| Median Negative | -5.8% | -9.9% | -18.1% |
| Max Positive | 31.0% | 44.9% | 86.7% |
| Max Negative | -22.3% | -23.5% | -30.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 11/09/2026 | 10-Q |
| 06/30/2026 | 08/10/2026 | 10-Q |
| 03/31/2026 | 05/11/2026 | 10-Q |
| 12/31/2025 | 02/23/2026 | 10-K |
| 09/30/2025 | 11/03/2025 | 10-Q |
| 06/30/2025 | 08/04/2025 | 10-Q |
| 03/31/2025 | 05/05/2025 | 10-Q |
| 12/31/2024 | 02/24/2025 | 10-K |
| 09/30/2024 | 11/04/2024 | 10-Q |
| 06/30/2024 | 08/05/2024 | 10-Q |
| 03/31/2024 | 05/06/2024 | 10-Q |
| 12/31/2023 | 02/26/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/08/2023 | 10-Q |
| 12/31/2022 | 02/27/2023 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 11/09/2026 | 10-Q |
| 06/30/2026 | 08/10/2026 | 10-Q |
| 03/31/2026 | 05/11/2026 | 10-Q |
| 12/31/2025 | 02/23/2026 | 10-K |
| 09/30/2025 | 11/03/2025 | 10-Q |
| 06/30/2025 | 08/04/2025 | 10-Q |
| 03/31/2025 | 05/05/2025 | 10-Q |
| 12/31/2024 | 02/24/2025 | 10-K |
| 09/30/2024 | 11/04/2024 | 10-Q |
| 06/30/2024 | 08/05/2024 | 10-Q |
| 03/31/2024 | 05/06/2024 | 10-Q |
| 12/31/2023 | 02/26/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/08/2023 | 10-Q |
| 12/31/2022 | 02/27/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| 06/30/2022 | 08/08/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 02/24/2022 | 10-K |
| 09/30/2021 | 11/10/2021 | 10-Q |
| 06/30/2021 | 08/11/2021 | 10-Q |
| 03/31/2021 | 05/17/2021 | 10-Q |
| 09/30/2020 | 02/05/2021 | S-1 |
Recent Forward Guidance
Updated 11/10/2026Latest: Q3 2026 Earnings Reported 11/9/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2026 Revenue | Reported | 875.00 Mil | 885.00 Mil | 895.00 Mil | -0.6% | Lower New | Guidance: 890.00 Mil for Q3 2026 | |
| Q4 2026 Adjusted EBITDA | Reported | 70.00 Mil | 80.00 Mil | 90.00 Mil | -5.9% | Lower New | Guidance: 85.00 Mil for Q3 2026 | |
| Q4 2026 Adjusted EBITDA Margin | Reported | 8.0% | 9.0% | 10.0% | -1.0% | Lower New | Guidance: 10.0% for Q3 2026 | |
| 2026 Revenue | Reported | 3.13 Bil | 3.14 Bil | 3.15 Bil | -1.9% | Lowered | Guidance: 3.20 Bil for 2026 | |
| 2026 Adjusted EBITDA | Reported | 257.00 Mil | 267.00 Mil | 277.00 Mil | -11.0% | Lowered | Guidance: 300.00 Mil for 2026 | |
| 2026 Adjusted EBITDA Margin | Reported | 8.0% | 8.5% | 9.0% | -1.0% | Lowered | Guidance: 9.5% for 2026 | |
Prior: Q2 2026 Earnings Reported 8/10/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q3 2026 Revenue | Reported | 880.00 Mil | 890.00 Mil | 900.00 Mil | 29.0% | Higher New | Guidance: 690.00 Mil for Q2 2026 | |
| Q3 2026 Adjusted EBITDA | Reported | 75.00 Mil | 85.00 Mil | 95.00 Mil | 88.9% | Higher New | Guidance: 45.00 Mil for Q2 2026 | |
| Q3 2026 Adjusted EBITDA Margin | Reported | 9.0% | 10.0% | 11.0% | ||||
| 2026 Revenue | Reported | 3.10 Bil | 3.20 Bil | 3.30 Bil | 10.3% | Raised | Guidance: 2.90 Bil for 2026 | |
| 2026 Adjusted EBITDA | Reported | 275.00 Mil | 300.00 Mil | 325.00 Mil | -4.0% | Lowered | Guidance: 312.50 Mil for 2026 | |
| 2026 Adjusted EBITDA Margin | Reported | 9.0% | 9.5% | 10.0% | ||||
Q1 2026 Earnings Reported 5/11/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q2 2026 Revenue | Reported | 680.00 Mil | 690.00 Mil | 700.00 Mil | 12.7% | Higher New | Actual: 612.50 Mil for Q1 2026 | |
| Q2 2026 Adjusted EBITDA | Reported | 35.00 Mil | 45.00 Mil | 55.00 Mil | 0 | Same New | Actual: 45.00 Mil for Q1 2026 | |
| 2026 Revenue | Reported | 2.80 Bil | 2.90 Bil | 3.00 Bil | 3.6% | Raised | Guidance: 2.80 Bil for 2026 | |
| 2026 Adjusted EBITDA | Reported | 275.00 Mil | 312.50 Mil | 350.00 Mil | -7.4% | Lowered | Guidance: 337.50 Mil for 2026 | |
Q4 2025 Earnings Reported 2/23/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Revenue | Reported | 600.00 Mil | 612.50 Mil | 625.00 Mil | -0.4% | Lower New | Guidance: 615.00 Mil for Q4 2025 | |
| Q1 2026 Adjusted EBITDA | Reported | 35.00 Mil | 45.00 Mil | 55.00 Mil | -25.0% | Lower New | Guidance: 60.00 Mil for Q4 2025 | |
| Q1 2026 Adjusted EBITDA Margin | Reported | 6.0% | 7.5% | 9.0% | -2.0% | Lower New | Guidance: 9.5% for Q4 2025 | |
| 2026 Revenue | Reported | 2.70 Bil | 2.80 Bil | 2.90 Bil | 19.4% | Higher New | Guidance: 2.35 Bil for 2025 | |
| 2026 Adjusted EBITDA | Reported | 300.00 Mil | 337.50 Mil | 375.00 Mil | 8.2% | Higher New | Guidance: 312.00 Mil for 2025 | |
| 2026 Adjusted EBITDA Margin | Reported | 11.0% | 12.0% | 13.0% | -1.0% | Lower New | Guidance: 13.0% for 2025 | |
Insider Activity
Updated 10/29/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Boughton, Soleil | Chief Legal Officer | Direct | Sell | 10292026 | 27.60 | 3,462 | 95,551 | 8,111,254 | Form |
| 2 | Boughton, Soleil | Chief Legal Officer | Direct | Sell | 10152026 | 29.06 | 3,461 | 100,577 | 8,640,933 | Form |
| 3 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 10022026 | 29.70 | 2,000 | 59,400 | 6,965,452 | Form |
| 4 | Boughton, Soleil | Chief Legal Officer | Direct | Sell | 10022026 | 29.17 | 3,461 | 100,957 | 8,774,599 | Form |
| 5 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 9232026 | 29.95 | 29,277 | 876,846 | 7,083,984 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Boughton, Soleil | Chief Legal Officer | Direct | Sell | 10292026 | 27.60 | 3,462 | 95,551 | 8,111,254 | Form |
| 2 | Boughton, Soleil | Chief Legal Officer | Direct | Sell | 10152026 | 29.06 | 3,461 | 100,577 | 8,640,933 | Form |
| 3 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 10022026 | 29.70 | 2,000 | 59,400 | 6,965,452 | Form |
| 4 | Boughton, Soleil | Chief Legal Officer | Direct | Sell | 10022026 | 29.17 | 3,461 | 100,957 | 8,774,599 | Form |
| 5 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 9232026 | 29.95 | 29,277 | 876,846 | 7,083,984 | Form |
| 6 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 9182026 | 28.82 | 12,313 | 354,861 | 7,256,991 | Form |
| 7 | Boughton, Soleil | Chief Legal Officer | Direct | Sell | 9172026 | 27.86 | 6,236 | 173,735 | 8,476,962 | Form |
| 8 | Chi, Michael | Chief Operating Officer | Direct | Sell | 9172026 | 28.39 | 14,027 | 398,227 | 12,964,577 | Form |
| 9 | Elshenawy, Mohamed | CTO | Direct | Sell | 9172026 | 28.39 | 7,954 | 225,814 | 5,267,935 | Form |
| 10 | Boughton, Soleil | Chief Legal Officer | Direct | Sell | 9032026 | 28.33 | 3,458 | 97,965 | 8,796,635 | Form |
| 11 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 8202026 | 29.99 | 4,938 | 148,111 | 7,921,978 | Form |
| 12 | Boughton, Soleil | Chief Legal Officer | Direct | Sell | 8202026 | 27.55 | 25,111 | 691,808 | 8,649,708 | Form |
| 13 | Autor, Deborah M | Chief Policy Officer | Direct | Sell | 8202026 | 27.85 | 16,773 | 467,128 | 1,363,564 | Form |
| 14 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 8182026 | 27.89 | 9,388 | 261,802 | 7,365,404 | Form |
| 15 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 8182026 | 35.09 | 55,383 | 1,943,389 | 8,033,434 | Form |
| 16 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 7202026 | 31.99 | 7,163 | 229,168 | 9,096,367 | Form |
| 17 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 7072026 | 36.49 | 7,163 | 261,351 | 10,373,821 | Form |
| 18 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 6232026 | 34.03 | 18,197 | 619,217 | 9,675,017 | Form |
| 19 | Carroll, Patrick Harrison | Chief Medical Officer | Direct | Sell | 6232026 | 35.00 | 23,726 | 830,410 | 6,365,135 | Form |
| 20 | Chi, Michael | Chief Operating Officer | Direct | Sell | 6172026 | 31.50 | 14,027 | 441,850 | 13,611,906 | Form |
| 21 | Becklund, Irene | PAO | Direct | Sell | 6172026 | 31.50 | 4,490 | 141,435 | 213,885 | Form |
| 22 | Elshenawy, Mohamed | CTO | Direct | Sell | 6172026 | 31.50 | 30,040 | 946,260 | 3,182,224 | Form |
| 23 | Becklund, Irene | PAO | Direct | Sell | 6172026 | 30.25 | 7,573 | 229,083 | 341,220 | Form |
| 24 | Wells, David B | Direct | Buy | 5262026 | 24.23 | 48,400 | 1,172,974 | 5,438,746 | Form | |
| 25 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 5192026 | 23.64 | 7,950 | 187,916 | 6,215,496 | Form |
| 26 | Boughton, Soleil | Chief Legal Officer | Direct | Sell | 4222026 | 30.00 | 9,463 | 283,890 | 8,981,040 | Form |
| 27 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 4222026 | 29.96 | 19,645 | 588,615 | 7,878,786 | Form |
| 28 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 4202026 | 27.83 | 18,005 | 501,158 | 7,516,568 | Form |
| 29 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 4202026 | 25.90 | 36,922 | 956,147 | 7,299,341 | Form |
| 30 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 4072026 | 19.98 | 3,975 | 79,409 | 6,368,448 | Form |
| 31 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 3242026 | 23.77 | 9,217 | 219,067 | 7,576,881 | Form |
| 32 | Becklund, Irene | PAO | Direct | Sell | 3182026 | 24.69 | 5,529 | 136,511 | 216,087 | Form |
| 33 | Boughton, Soleil | Chief Legal Officer | Direct | Sell | 3182026 | 24.69 | 4,812 | 118,808 | 7,625,037 | Form |
| 34 | Chi, Michael | Chief Operating Officer | Direct | Sell | 3182026 | 24.69 | 97,289 | 2,402,065 | 10,055,793 | Form |
| 35 | Boughton, Soleil | Chief Legal Officer | Direct | Sell | 3022026 | 15.21 | 4,651 | 70,742 | 6,707,184 | Form |
| 36 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 2042026 | 26.44 | 5,262 | 139,108 | 2,422,014 | Form |
| 37 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 1212026 | 30.34 | 9,067 | 275,114 | 2,779,870 | Form |
| 38 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 12232025 | 35.72 | 23,090 | 824,710 | 3,369,311 | Form |
| 39 | Chi, Michael | Chief Operating Officer | Direct | Sell | 12182025 | 36.71 | 13,750 | 504,762 | 11,202,460 | Form |
| 40 | Autor, Deborah M | Chief Policy Officer | Direct | Sell | 12182025 | 36.71 | 7,054 | 258,952 | 226,684 | Form |
| 41 | Carroll, Patrick Harrison | Chief Medical Officer | Direct | Sell | 12182025 | 36.71 | 10,021 | 367,871 | 6,238,497 | Form |
| 42 | Becklund, Irene | PAO | Direct | Sell | 12182025 | 36.71 | 8,411 | 308,768 | 78,045 | Form |
| 43 | Perez, Garcia Andrea G | Direct | Sell | 12102025 | 39.17 | 2,500 | 97,925 | 3,140,102 | Form | |
| 44 | Boughton, Soleil | Chief Legal Officer | Direct | Sell | 11252025 | 35.22 | 2,631 | 92,664 | 5,396,584 | Form |
| 45 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 11192025 | 36.81 | 23,187 | 853,490 | 2,585,170 | Form |
| 46 | Boughton, Soleil | Chief Legal Officer | Direct | Sell | 11122025 | 42.53 | 2,637 | 112,152 | 6,628,556 | Form |
| 47 | Boughton, Soleil | Chief Legal Officer | Direct | Sell | 10282025 | 50.10 | 2,637 | 132,114 | 7,940,499 | Form |
| 48 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 10202025 | 57.13 | 11,592 | 662,222 | 4,012,179 | Form |
| 49 | Dudum, Andrew | Chief Executive Officer | Direct | Sell | 10202025 | 62.78 | 128,127 | 8,043,237 | 5,808,178 | Form |
| 50 | Dudum, Andrew | Chief Executive Officer | Held by Trustee of Dudum Family Community Property Trust | Sell | 10202025 | 62.83 | 47,534 | 2,986,761 | 2,986,133 | Form |
| 51 | Boughton, Soleil | Chief Legal Officer | Direct | Sell | 10142025 | 54.38 | 2,637 | 143,400 | 8,762,249 | Form |
| 52 | Chi, Michael | Chief Commercial Officer | Direct | Sell | 10142025 | 58.25 | 900 | 52,425 | 16,976,322 | Form |
| 53 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 10072025 | 57.72 | 11,595 | 669,232 | 4,053,601 | Form |
| 54 | Chi, Michael | Chief Commercial Officer | Direct | Sell | 10022025 | 56.00 | 250 | 14,000 | 16,320,584 | Form |
| 55 | Okupe, Oluyemi | Chief Financial Officer | Direct | Sell | 9302025 | 60.20 | 85,000 | 5,116,924 | 4,227,903 | Form |
| 56 | Boughton, Soleil | Chief Legal Officer | Direct | Sell | 9302025 | 58.79 | 2,637 | 155,029 | 9,627,862 | Form |
Investor Activity (13F)
Updated Nov 12, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Health Care Services Resources |
| HealthLeaders Media |
| Medical Economics |
| Physicians Practice |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 11/11/2026